Hamburg University Cardiovascular Center, Hamburg, Germany Background: Bioresorbable vascular scaffolds have been available on the European market since November 2011. The first experience in a real-world setting is being documented in the ASSURE registry (NCT01583608). The registry aims to investigate the safety, efficacy and performance of the everolimus-eluting, bioresorbable vascular scaffold (BVS, ABSORBÔ, Abbott Vascular Inc., Santa Clara, CA) over a period of 3 years. Methods: Consecutive patients with de novo native coronary artery disease were treated with BVS at 6 German centers and included in the prospective, observational registry. Acute and 6-months outcomes of equal weight were device success, procedural success, cardiac death, myocardial infarction, ischemia driven target lesion revascularization and target vessel failure or revascularization. Angiographic parameters were assessed at baseline and post procedure. Results: A total of 183 patients (63.5 AE 9.3 years, 79.8% male) were enrolled from April 2012 to March 2013 and 198 lesions were treated. Eligibility criteria for ABSORB A/B would have been met in 16% and for ABSORB EXTEND in 70% of the patients. Acute device success was achieved in 194 (98%) lesions and acute procedural success in all patients. No cardiac death or myocardial infarction occurred and no target lesion revascularization was necessary during hospital stay. Median lesion length was 14.5 mm (5-84 mm) with 85 (42.9%) lesions > 20 mm. 31 (15.7%) lesions were moderately or heavily calcified, 6 (3%) lesions were tightly angulated and 6 (3%) lesions involved a side branch ! 2 mm in diameter. Diameter stenosis was 77.9% at baseline and 4.8% post PCI on average. In 11 (5.6%) lesions diameter of stenosis was ! 99%. The reference vessel diameter of 32 (16.2%) lesions was 2.5 mm. In 30 (15.2%) lesions > 1 BVS was implanted and in 11 patients > 1 target vessel was treated. Bailout with a drug eluting stent was necessary in 3 (1.5%) lesions. Conclusions: Acute results for safety, efficacy and performance of BVS for de novo coronary artery disease in all day clinical practice are promising. Angiographic core lab results will be obtained by June 2013 and clinical 6-months results by September 2013.
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Malapposition is observed more frequently and to a greater degree in fibrocalcific plaques during bioresorbable vascular scaffold implantation Background: The bioresorbable vascular scaffold (BVS) has several advantages over existing metallic stents, including resorption and restoration of vasoreactivity. However, the mechanical properties of the BVS do not allow aggressive post-dilatation, with potential for malapposition. Our aim was to assess the incidence of malapposition and relation to plaque characteristics. Methods: 22 patients undergoing BVS implantation were included (77.3% male; age 60.1AE11.2yrs). Optical coherence tomography (OCT) was performed before/after implantation. Two experienced OCT operators analyzed runs at 1mm longitudinal intervals; where malapposition was seen, analysis was performed at 0.2mm intervals. Malapposition was adjudicated and quantified, defined as strut with 50% contact of abluminal strut surface with endothelium. Tissue characterisation was defined as the predominant plaque composition in the quadrant of each strut. The degree of malapposition was measured from adluminal strut edge to endothelium in a radial direction, with strut width being 0.158mm. Results: Target lesion was LAD 12, RCA 6, Cx 2 and SVG 2. Calcification was absent (81.8%), mild (4.5%) and moderate (13.6%) on independent review. Median number of BVS implanted was 1 (median size 3.0x18mm). Agreement on OCTdefined strut malapposition between observers was excellent (Kappa 0.847). In total, 766 frames of OCT were analysed (median 29.5 per case). 6798 struts were identified with 436 (6.85%) being malapposed. Number of malapposed struts varied significantly (range 0-147, median 5, IQR 1-29). Fibrocalcific plaque was more prevalent when malapposition was present (46.6% vs. 8.3%, p<0.001). There was a positive correlation between %calcification and malapposition (r¼0.44, p<0.001). The distance of malapposition in fibrocalcific plaque was increased compared to other malapposed struts (0.17mmAE0.10 vs. 0.14mmAE0.07, p¼0.01). Conclusions: Incidence of strut malapposition with BVS is comparable to existing DES platforms. However, malapposition is more frequent and occurs to a greater degree in fibrocalcific plaques. Intracoronary imaging should be considered prior to BVS, as unrecognized calcification may lead to unnecessary malapposition. Auckland City Hospital, Auckland, New Zealand Background: While bifurcation stenting techniques with metallic stents have been extensively studied on the bench and clinically, there are no data on how to treat bifurcations with Absorb everolimus-eluting bioresorbable scaffolds (BRS) which have limited post-dilatation potential without strut rupture compared with metallic scaffolds. Methods: BRS were deployed in phantoms with 30
, 60 and 90 side-branch angles in water at 37 C for testing strategies including side-branch dilatation with 2.5 and 3.0mm balloons, main branch post-dilatation, kissing post-dilatation at 4 atmospheres pressure and minimal balloon overlap, proximal optimization, "T" stenting with BRS and with metallic stents, "T" with protrusion, Culotte technique, "Crush" technique, SKS technique. The deployment steps were recorded using cine-angiography and final results of each technique were recorded photographically and with micro-computed tomographic images. Results: Dilating through the side of a BRS produced distortion similar to that with metallic stents that was worse with smaller side-branch angles and bigger balloons. The distortion consisted of narrowing of the scaffold beyond the side-branch and malapposition of the struts opposite the side branch. The positive effect of distortion occurred, with protrusion of struts into the side-branch. The distortion could be partially repaired by main branch post-dilatation but was best repaired by low pressure kissing post-dilatation. An unique feature of BRS use in bifurcations is the occurrence of single scaffold hoop or connector rupture. These are of uncertain significance. Conclusions: Bench deployments of BRS provide insights into bifurcation strategies with these unique devices that behave differently from metallic scaffolds.
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Bifurcation FEops / Ghent University, Gent, Belgium Background: Little is known about bifurcation treatment with the bioresorable vascular scaffold (BVS) from Abbott. In a bench test we investigated the mechanical properties and integrity of BVS in different bifurcation models Methods: In a warm water bath of 36 degrees Celsius multiple BVS were tested in 2 models. Model A. Opening towards an artificial side branch (SB) of a 3.0 mm BVS was investigated with increasing balloon sizes through a mid BVS cell under an angle of 30 and 60 degrees. Model B. With a 3D printer, 6 bifurcation models consisting of a rubber-like material (TangoPlus) with moderate stenosis (Medina 1-1-0) and 60 degree SB angle were made with the proper sizing of the proximal main branch (PMB), SB and distal main branch (DMB) using a validated scaling law. In these models 2.5, 3.0 and 3.5 mm BVS were implanted in the MB. Sequentially, SB opening was done using single 2.0 or 2.5 mm balloons (4 models) or using 2.0 and 3.0 mm balloons for complete (1 model) and incomplete kissing/snuggle (1 model). Opening and distortion of the BVS struts were investigated with OCT and microCT. Results: In model A, without surrounding structures, a cell of a 3.0 mm BVS can be expanded with 1.5 and 2.5 mm balloons at high pressure (16 atm) without disrupting struts. With a 3.0 balloon at 30 degree angle at 10 atm. and with 3.5 balloon at 60 degree angle at 8 atm. 1 or more struts ruptured. In model B, all 3D models showed no strut ruptures by OCT. By microCT only one partial strut tear was seen after incomplete kissing balloon. By OCT and microCT identical scaffold distortions of the PMB and DMB were observed, similar to what has been described with metallic stents. Distal struts adjacent to the SB were deflected into the lumen and proximal struts adjacent to the SB were deflected towards the SB opening. Furthermore, struts opposite the SB were deflected inwards causing malapposition. Increasing SB balloon size showed increased malapposition up to 270 um. With double balloon inflation technique no malapposition was noted. Conclusions: These results support the concept that bifurcation treatment with BVS is feasible and that similar strategies for provisional sidebranch treatment apply as to metallic stent.
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Real-World Experience with AbsorbÔ Bioresorbable Scaffold TechnologyEarly Australian Registry Results Background: The safety and efficacy of the AbsorbÔ bioresorbable scaffold (ABS) has been documented in lower-risk lesion subsets however outcome data in more www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
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